By IDSE News Staff
The FDA has granted Breakthrough Device designation to a new rapid diagnostic blood test for sepsis (MeMed Severity, MeMed).
Built for use in emergency departments, the test uses host response technology to measure multiple proteins in a blood sample and then risk-stratifies patients using a machine learning algorithm. The test, which produces results in less than 15 minutes, can signify whether a patient may be at risk for severe outcomes within 72 hours or death within 14